Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Tumorigenicity of IL-1α- and IL-1β-Deficient Fibrosarcoma Cells" [Neoplasia, Volume 10, Issue 6, June 2008, Pages 549-562].
Nazarenko I, Marhaba R, Reich E, Voronov E, Vitacolonna M, Hildebrand D, Elter E, Rajasagi M, Apte RN, Zöller M. Nazarenko I, et al. Among authors: rajasagi m. Neoplasia. 2024 Dec 28;60:101087. doi: 10.1016/j.neo.2024.101087. Online ahead of print. Neoplasia. 2024. PMID: 39733692 Free article. No abstract available.
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, Yu EY, Montesa Pino A, Anido U, Sendur MAN, Gravis G, Révész J, Kostorov V, Huillard O, Ma J, Rajasagi M, Vajdi A, Lunceford J, Cristescu R, Imai K, Homet Moreno B, Matsubara N. Fléchon A, et al. Among authors: rajasagi m. Clin Cancer Res. 2024 Dec 2;30(23):5353-5364. doi: 10.1158/1078-0432.CCR-23-3518. Clin Cancer Res. 2024. PMID: 39475359 Free PMC article. Clinical Trial.
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, Choueiri TK, Culine S, Gerritsen W, Gurney H, Quinn DI, Vuky J, Vogelzang NJ, Cristescu R, Lunceford J, Saadatpour A, Loboda A, Ma J, Rajasagi M, Godwin JL, Homet Moreno B, Grivas P. Bellmunt J, et al. Among authors: rajasagi m. Clin Cancer Res. 2022 May 13;28(10):2050-2060. doi: 10.1158/1078-0432.CCR-21-3089. Clin Cancer Res. 2022. PMID: 35247908 Clinical Trial.
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.
Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, Stevens J, Lane WJ, Dellagatta JL, Steelman S, Sougnez C, Cibulskis K, Kiezun A, Hacohen N, Brusic V, Wu CJ, Getz G. Shukla SA, et al. Among authors: rajasagi m. Nat Biotechnol. 2015 Nov;33(11):1152-8. doi: 10.1038/nbt.3344. Nat Biotechnol. 2015. PMID: 26372948 Free PMC article.
HLA-binding properties of tumor neoepitopes in humans.
Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. Fritsch EF, et al. Among authors: rajasagi m. Cancer Immunol Res. 2014 Jun;2(6):522-9. doi: 10.1158/2326-6066.CIR-13-0227. Epub 2014 Mar 3. Cancer Immunol Res. 2014. PMID: 24894089 Free PMC article. Review.
CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells.
Naito M, Hainz U, Burkhardt UE, Fu B, Ahove D, Stevenson KE, Rajasagi M, Zhu B, Alonso A, Witten E, Matsuoka K, Neuberg D, Duke-Cohan JS, Wu CJ, Freeman GJ. Naito M, et al. Among authors: rajasagi m. Cancer Immunol Immunother. 2013 Feb;62(2):347-57. doi: 10.1007/s00262-012-1331-4. Epub 2012 Aug 25. Cancer Immunol Immunother. 2013. PMID: 22926059 Free PMC article.
13 results